Journal of Pharmaceutical Research

H. V. Anuradha ¹, H. P. Pundarikaksha ², H. N. Sowbhagya ³, N. V. V. Himamshu ³

Affiliations
1 Department of Pharmacology, M S Ramaiah Medical College, Bangalore-54, IN
2 Department of Pharmacology, KempeGowda Institute of Medical Science, Bangalore-96, IN
3 Department of Ophthalmology, KempeGowda Institute of Medical Science, Bangalore-4, IN

Abstract

The drugs currently available for treatment of glaucoma are α-blockers, sympathomimetics, carbonic anhydrase inhibitors (CAIs) and prostaglandin analogues1. Apart from their use in glaucoma to reduce IOP, the antiglaucoma drugs are also used routinely for pre-operative reduction of IOP even in nonglaucomatous patients subjected for intraocular surgery to prevent expulsive haemorrhage and bulging of anterior segment.

Objectives: To assess the safety and tolerability of 2% dorzolamide and 0.5% timolol maleate in Pre-operative Cataract patients.

Materials and Methods: A prospective, comparative study enrolling 60 Pre-operative Cataract patients (30 in each group) attending Ophthalmology inpatient department in Kempe Gowda Institute of Medical Science Hospital and Research Centre. Dorzolamide was instilled thrice daily and timolol maleate twice daily for 2 days. IOP was measured on zero, 2^nd, 24^th and 48^th hours and also looked for side effects.

Results: The mean reduction of IOP was 17.1% with dorzolamide and 18.9% with timolol maleate. Both the drugs were tolerated very well without any systemic adverse effect and the local side effects were comparatively less with dorzolamide.

Conclusion: Efficacy of dorzolamide in decreasing IOP in Pre-operative Cataract patients was almost comparable to timolol, and dorzolamide appeared to be relatively better tolerated.

Keywords

Pre-Operative, Cataract, IOP, Dorzolamide, Timolol Maleate.

Full Text

   

H. V. Anuradha ¹, H. P. Pundarikaksha ², N. V. V. Himamshu ³

Affiliations
1 Department of Pharmacology, M.S.Ramaiah Medical College, Bangalore-560054, IN
2 Department of Pharmacology , Kempe Gowda Institute of Medical Science, Bangalore-560070, IN
3 Department of Ophthalmology, Kempe Gowda Institute of Medical Science, Bangalore-560070, IN

Abstract

Primary open angle glaucoma (POAG), the most common form of glaucoma, left untreated results in gradual loss of vision. Decreasing intra ocular pressure (IOP) by drugs can halt disease progression. The drugs currently available for treatment of POAG are-blockers, sympathomimetics, carbonic anhydrase inhibitors (CAIs) and prostaglandin analogues. To assess the safety and tolerability of 2% dorzolamide and 0.5% timolol maleate in POAG patients, a prospective, comparative study was undertaken, enrolling 60 patients with POAG (30 in each group) attending Ophthalmology out patient department in Kempe Gowda Institute of Medical Science hospital and research centre. Dorzolamide was instilled thrice daily and timolol maleate twice daily for 28days. IOP was measured on day zero, 14th and 28th day. Visual acuity and side effects were looked for at each visit.

The mean reduction of IOP was 19.95% with dorzolamide and 21.5% with timolol maleate. Both the drugs were tolerated very well without any systemic adverse effects and the local side effects were comparatively less with dorzolamide. Efficacy of dorzolamide in decreasing IOP in POAG patients was almost comparable to timolol, and dorzolamide appeared to be relatively better tolerated.

Keywords

POAG, IOP, Dorzolamide, Timolol Maleate.

Full Text